title: Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.
abstract: The fifth paper in this series describes the culmination of our investigations into the development of a potent and selective ET(A) receptor antagonist for the treatment of diseases mediated by ET-1. Receptor site mapping of several ET(A) antagonists prepared previously identified a common cationic binding site which prompted synthesis of phenoxyphenylacetic acid derivative 13a, which showed good in vitro activity (IC(50) 59 nM, rat aortic ET(A)). Optimization of 13a led to the identification of 27b, which exhibited an IC(50) of 4 nM. Although this did not translate into the expected in vivo potency, a compound of comparable in vitro activity, 27a (RPR118031A), showed a far better pharmacokinetic profile and in vivo potency (75 micromol/kg) and was duly proposed and accepted as a development candidate.
authors.affiliation: Rhône-Poulenc Rorer, Dagenham Research Centre, Rainham Road South, Dagenham, Essex, RM10 7XS U.K.
authors.forename: P C
authors.initials: PC
authors.lastname: Astles
authors.forename: T J
authors.initials: TJ
authors.lastname: Brown
authors.forename: F
authors.initials: F
authors.lastname: Halley
authors.forename: C M
authors.initials: CM
authors.lastname: Handscombe
authors.forename: N V
authors.initials: NV
authors.lastname: Harris
authors.forename: T N
authors.initials: TN
authors.lastname: Majid
authors.forename: C
authors.initials: C
authors.lastname: McCarthy
authors.forename: I M
authors.initials: IM
authors.lastname: McLay
authors.forename: A
authors.initials: A
authors.lastname: Morley
authors.forename: B
authors.initials: B
authors.lastname: Porter
authors.forename: A G
authors.initials: AG
authors.lastname: Roach
authors.forename: C
authors.initials: C
authors.lastname: Sargent
authors.forename: C
authors.initials: C
authors.lastname: Smith
authors.forename: R J
authors.initials: RJ
authors.lastname: Walsh
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D001667:Binding, Competitive; D001682:Biological Availability; D002460:Cell Line; D002531:Cerebellum / Q000378:metabolism; D003655:Decerebrate State; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000378:metabolism; D066298:In Vitro Techniques; D008958:Models, Molecular; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000502:physiology; D010648:Phenylacetates / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: C406228:2-(2-cyano-5-(pyrid-4-yl)methoxy)phenoxy-2-(2-methyl)phenylacetic acid; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D010648:Phenylacetates; D011725:Pyridines; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin